|
Market Closed -
Other stock markets
|
After hours 01:00:00 | |||
| 983.26 USD | -2.02% |
|
971.63 | -1.18% |
| 08:30am | Zealand Pharma slump wipes billions off company value after obesity drug data disappoints | RE |
| 05:37am | China approves Pfizer GLP-1 drug for weight loss | RE |
Evolution of the Average Target: Eli Lilly and Company
Evolution of the Target Price: Eli Lilly and Company
Changes in Analyst Recommendations: Eli Lilly and Company
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +23.5% | |||||
| -1.83% | |||||
| +7.11% | |||||
| +2.63% | |||||
| +10.94% | |||||
| -5.88% | |||||
| +9.61% | |||||
| -4.78% | |||||
| +7.89% | |||||
| +33.1% | |||||
| Average | +8.23% | |||||
| Weighted average by Cap. | +9.23% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Guggenheim | |
| RBC Capital Markets | |
| Rothschild & Co Redburn | |
| Berenberg Bank | |
| Daiwa Securities | |
| CICC Research | |
| Deutsche Bank Securities | |
| Argus | |
| Truist Securities | |
| Wells Fargo Securities | |
| Morgan Stanley | |
| JPMorgan Chase | |
| Cantor Fitzgerald | |
| BMO Capital | |
| Goldman Sachs | |
| Scotiabank | |
| Leerink Partners | |
| TD Cowen | |
| Jefferies & Co. | |
| UBS | |
| HSBC | |
| Wolfe Research | |
| Bernstein | |
| Citigroup | |
| China Merchants | |
| DBS Bank | |
| First Shanghai | |
| BofA Securities | |
| Redburn Atlantic | |
| JEFFERIES | Akash Tewari |
| Barclays | |
| China International Capital | |
| DZ Bank | |
| Morningstar | |
| Credit Suisse | |
| SVB Securities LLC | |
| Cowen | |
| Mizuho Securities |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LLY Stock
- Consensus Eli Lilly and Company
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition